Global | January 2026 — GlaxoSmithKline PLC (GSK) achieved key milestones in 2025, with multiple regulatory approvals, product launches, and label expansions across vaccines, respiratory, and immunology, reinforcing its strategy of science-driven innovation and global patient access. The year reflects a focused execution on high-value specialty and preventative medicines, positioning GSK for sustained growth in 2026.
Vaccines Portfolio: Driving Global Immunization Leadership
Shingrix® — Herpes Zoster Vaccine
Condition: Prevention of shingles in adults
In 2025, Shingrix received approvals in additional markets, enabling broader access to the vaccine and supporting GSK’s vaccine leadership strategy.
Strategic Impact:
Shingrix continues to drive premium vaccine revenue and strengthens GSK’s position in preventive healthcare globally.
Bexsero® and Menveo® — Meningococcal Vaccines
Condition: Prevention of meningococcal disease
GSK expanded access to meningococcal vaccines in key regions during 2025, complementing its global immunization portfolio.
Respiratory Portfolio: Specialty Therapy Growth
Nucala® — Severe Eosinophilic Asthma
Condition: Severe asthma
Nucala maintained global adoption in 2025, supported by label expansions and payer access programs, reinforcing GSK’s specialty respiratory franchise.
Trelegy Ellipta® — COPD
Condition: Chronic obstructive pulmonary disease
Trelegy adoption grew steadily in 2025 with increased guideline inclusion and patient access initiatives, contributing to sustainable franchise growth.
Immunology Portfolio: Advancing Targeted Therapies
Jemperli® — Endometrial Cancer
Condition: Advanced or recurrent endometrial cancer
Jemperli received expanded approvals in 2025 for use in combination therapies, reinforcing GSK’s precision oncology strategy.
Benlysta® — Systemic Lupus Erythematosus (SLE)
Condition: Autoimmune disease
Benlysta maintained uptake in 2025, supported by additional indications and global launch efforts, strengthening GSK’s immunology leadership.
Digital, AI, and R&D Enablement
GSK leveraged AI, predictive analytics, and digital platforms in 2025 to:
- Accelerate vaccine and specialty therapy research
- Optimize clinical trial design and patient recruitment
- Enhance commercial forecasting and launch efficiency
Strategic Impact:
AI integration boosts R&D productivity, launch precision, and patient-centric outcomes, supporting long-term growth.
Looking Ahead: 2026 and Beyond
GSK enters 2026 with:
- A strengthened vaccine and specialty medicine portfolio
- Growing respiratory and immunology franchises
- AI-enabled insights driving research, development, and commercial excellence
The company’s 2025 approvals and launches provide a solid foundation for continued innovation, patient access, and revenue growth in 2026.
Conclusion
GSK’s 2025 execution demonstrates focused portfolio expansion, specialty therapy leadership, and global vaccine impact. With strategic approvals and launches, the company is well-positioned to deliver innovation, patient benefit, and sustainable growth well into 2026.
By